Back to Conditions

Tofacitinib: JAK Inhibitors and Who Can Take Them

Tofacitinib: JAK Inhibitors and Who Can Take Them
Prescription Medicines Editorial 31 August 2025

Tofacitinib blocks Janus kinases, enzymes that carry signals from a wide range of inflammatory cytokine receptors into the cell nucleus. Blocking that step damps down many inflammatory pathways at once. It is used in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and ankylosing spondylitis, and its great practical advantage over biologics is that it is a tablet. A large safety trial then changed who can be given it.

Follow the plan your specialist gave you. This guide contains no doses.

What the safety trial found

A post-authorisation trial in rheumatoid arthritis patients aged over 50 with at least one cardiovascular risk factor compared tofacitinib with TNF inhibitors.

It found higher rates of major cardiovascular events, cancers, blood clots, serious infections and death on tofacitinib.

Regulators including the MHRA responded with restrictions applying to JAK inhibitors as a class.

The restrictions

JAK inhibitors should be used only if no suitable alternative exists in people who:

  • Are aged 65 or over
  • Are current or long-term former smokers
  • Have cardiovascular risk factors - such as previous heart attack or stroke, diabetes, hypertension
  • Have risk factors for cancer

Caution also applies where there are risk factors for blood clots - previous clot, major surgery, immobility, combined hormonal contraception or hormone replacement therapy, and cancer.

The lowest effective dose should be used, and treatment reviewed regularly.

If you fall into one of those groups and are taking a JAK inhibitor, that is not a reason to stop unilaterally - it is a reason to have the conversation at your next review.

Shingles

JAK inhibitors carry a notably increased risk of herpes zoster - shingles - higher than with biologics, and higher again at greater doses.

It can be severe and multi-dermatomal.

Vaccination against shingles should be considered before starting, using the non-live vaccine, which is suitable for people who are immunosuppressed.

Report a painful blistering rash promptly - antiviral treatment works best started within 72 hours. See valaciclovir.

Screening before starting

As with TNF inhibitors, tuberculosis screening is required - history, chest X-ray and an interferon gamma release assay - along with hepatitis B and C serology.

Latent TB is treated before or alongside.

Blood counts, liver function and lipids are checked at baseline.

See adalimumab.

Monitoring during treatment

Lipids rise on JAK inhibitors, typically within the first weeks, and are checked a couple of months after starting. A statin is frequently added.

Lymphocyte, neutrophil and haemoglobin counts are monitored, and treatment is interrupted if they fall below thresholds.

Liver function is checked periodically. Creatine kinase can rise.

See monitoring long-term medicines and pravastatin.

Infection

Serious infections are more common, and the usual signs can be blunted.

Seek medical advice promptly for fever, persistent sore throat, a cough that will not settle, burning on passing urine, or a wound that is not healing.

Treatment is paused during a significant infection and restarted once it has resolved.

Live vaccines are avoided. Inactivated vaccines - influenza, pneumococcal, COVID and the non-live shingles vaccine - are recommended.

Carry your alert card and show it to anyone treating you.

See infection risk on immune-suppressing medicines.

Blood clots

Seek urgent help for pain, swelling or redness in a calf, or sudden breathlessness, chest pain or coughing blood.

Tell your prescriber about any previous clot, and about hormonal contraception or HRT.

Interactions

Tofacitinib is cleared by CYP3A4 and CYP2C19. Strong inhibitors including fluconazole and clarithromycin raise levels, and the dose is reduced.

Strong inducers such as rifampicin and carbamazepine reduce effectiveness.

See clarithromycin.

It is not combined with biologics or with potent immunosuppressants such as azathioprine and ciclosporin.

The other JAK inhibitors

Baricitinib, upadacitinib, filgotinib and abrocitinib work on the same enzyme family with differing selectivity between the JAK subtypes.

The regulatory restrictions described above apply to the class rather than to tofacitinib alone, since the safety data was extrapolated. Whether the more selective agents carry the same risk is not yet settled, and it is an active question - but current advice treats them together.

Why it is still used

For people who cannot or will not use injections, and for those in whom biologics have failed, a tablet that works as well as an injected biologic is valuable.

Its effect also comes on quickly, and it can be stopped quickly if a problem develops - which an injected antibody with a long half-life cannot.

The restrictions narrow who it suits rather than removing it.

If you are on one and it is working, the sensible approach is a conversation at review about whether you fall into a restricted group and whether an alternative would suit - not stopping a treatment that is controlling your disease.

See also Tizanidine: Muscle Spasm and One Antibiotic to Avoid, and the Conditions section for more on what medicines are prescribed for.